Advanced Hematologic Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

Optimizing outcomesAllogeneic transplantsAdvanced hematologicHematologic malignanciesHematologic cancersAllo hsctAllogeneic transplantAllo transplantHigh riskAdvanced hematologic malignanciesInvestigational allo hsct